Skip to main content
Fig. 4 | Diabetology & Metabolic Syndrome

Fig. 4

From: Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway

Fig. 4

KLF-5 mediated the protective effect of dapagliflozin in podocytes injury. (A) RT-PCR was employed to detect the knockdown efficiency of three different si-RNA specific for KLF-5(si-KLF-5). (B) WB was also used to detect the knockdown efficiency. (C) KLF-5 rescue experiments showed that si-KLF-5 could rescue the expression of ABCA1, which was upregulated in high glucose plus dapagliflozin. (D) The rescue experiment showed that si-KLF-5 on the basis of high glucose plus dapagliflozin could accelerate apoptosis and cell injury. (E) It is found that si-KLF-5 could restore the amount of cholesterol in podocyte on the basis of high glucose plus dapagliflozin when compared with high glucose plus dapagliflozin group. (F) Nile red showed similar results as (E). (G) Phalloidin staining showed KLF-5 mediated the effect of dapagliflozin on cytoskeleton. (Data presented are the mean ± S.D.; *P < 0.05 vs. HG, # P < 0.05 vs. HG + dapa, n = 3)

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us